Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

6:21 AM ET 10-Q
Financial Results Blue Biofuels, Inc. BIOF

Blue Biofuels Q3 2026 Results: Net Loss of $1.39M, Loss Widens

Blue Biofuels, Inc. reported a net loss of $2,799,864 for the nine months ended September 30, 2026, compared to a loss of $1,587,132 in the prior year period. The company remains in the development stage with zero revenue, while operating expenses increased due to higher research and development costs and stock-based compensation.

Key figure
Net loss $1.39M
6:20 AM ET 10-Q
Financial Results First Choice Healthcare Solutions, Inc. FCHS

First Choice Healthcare Solutions Q3 2026 Results: Net Loss of $10.7M, Loss Widens

First Choice Healthcare Solutions reported a significant net loss of $19.1 million for the nine months ended September 30, 2026, primarily driven by $17.4 million in interest expense. The company is currently pivoting its strategy toward a network of nurse practitioner-driven primary care clinics despite having zero revenue in the current period.

Key figure
Net loss $10.7M
6:07 AM ET 10-Q
Financial Results OpenWorld, Inc. OPNW ▶ Call

OpenWorld Q3 2026 Results: Net Loss of $10.2M

OpenWorld, Inc. reported a significant net loss of $16.1 million for the nine months ended September 30, 2026, compared to a net income of $1.0 million in the prior year, primarily driven by a decrease in total revenues and a sharp increase in general and administrative expenses. The period was marked by a reverse acquisition of VerifyMe, Inc. and substantial non-cash stock-based compensation and professional fees totaling over $12 million.

Key figure
Net loss $10.2M
6:06 AM ET 10-Q
Financial Results Hyperion Defi, Inc. HYPD

Hyperion Defi Q3 2026 Results: Net Income $39.6M, Up 497.5% YoY

Hyperion DeFi, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $79.4 million compared to a net loss of $5.5 million in the prior year, primarily driven by $93.6 million in realized and unrealized gains on digital assets. Total assets grew to $146.3 million from $51.8 million at year-end 2025, reflecting substantial appreciation in the company's digital asset holdings.

Key figure
Net income $39.6M · +497.5% YoY
6:06 AM ET 10-Q
Financial Results King Resources, Inc. KRFG

King Resources Global Q2 2026 Results: Net Loss of $522K, Loss Widens

King Resources Global, Inc. is a Nevada holding company operating through subsidiaries in Hong Kong and the British Virgin Islands. The company reported 112,616,649 shares of common stock outstanding as of October 21, 2026, and is currently navigating significant regulatory risks related to PRC oversight and the Holding Foreign Companies Accountable Act.

Key figure
Net loss $522K
6:06 AM ET 8-K
Financial Results Presidio Production Co FTW

Presidio Production Financial Results

Presidio Production Company reported Q3 2026 financial results, featuring a 15% increase in net production to 26.1 MBoe/d following the acquisition of Canyon Creek. The company reported total revenue of $57.3 million and Adjusted EBITDA of $29.1 million, while declaring an increased quarterly dividend of $0.375 per share.

Term
Q3 2026

“Our third quarter results reflect continued execution of our acquisition and optimization strategy. Canyon Creek contributed its first full quarter, and our continued focus on improving the performance of our existing assets has allowed us to increase our annualized dividend to $1.50 per share. Each of these steps reinforces the acquisition model we are building to consolidate producing oil and gas assets.”

Will Ulrich, Chairman and Co-CEO

“When we closed Canyon Creek, we said the Arkoma Basin was a place to build scale through consolidation. In our first full quarter operating the assets, we moved the wells onto our production systems, right-sized compression and changed chemical vendors, and Canyon Creek helped lower our lease operating expense per Boe.”

Chris Hammack, Co-CEO and Director
6:06 AM ET 10-Q
Financial Results TCW Specialty Lending IX LLC

TCW Specialty Lending IX Q3 2026 Results: Net Income $0

TCW Specialty Lending IX LLC is a newly formed business development company that has not yet commenced investment operations as of September 30, 2026. The company reported total assets of $484,830, primarily consisting of receivables from its investment adviser for organizational and offering costs, with a net asset value of $1,000. All operating expenses incurred since inception have been reimbursed by the Investment Adviser, resulting in zero net investment income.

Key figure
Net income $0
6:05 AM ET 10-Q
Financial Results TCW Star Direct Lending LLC

TCW Star Direct Lending Q3 2026 Results: Net Income $3.2M, Down 67.0% YoY

TCW Star Direct Lending LLC reported total investments at fair value of approximately $238 million as of September 30, 2026, with a portfolio primarily consisting of senior secured debt. The company maintains a diversified industry exposure, with significant concentrations in Food Products, Hotels, Restaurants & Leisure, and Personal Care Products.

Key figure
Net income $3.2M · -67.0% YoY
6:05 AM ET 10-Q
Financial Results Tcw Specialty Lending LLC

Tcw Specialty Lending Q3 2026 Results: Net Income $5.37M

TCW Specialty Lending LLC is a newly formed business development company that commenced operations on March 2, 2026. As of September 30, 2026, the company held a diversified portfolio of debt investments across various industries, with its largest exposures in Electrical Equipment (14.9% of net assets) and Building Products (12.1% of net assets).

Key figure
Net income $5.37M
6:05 AM ET 10-Q
Financial Results TCW Steel City Senior Lending BDC

TCW Steel City Senior Lending BDC Q3 2026 Results: Net Income $7.39M, Up 427.8% YoY

TCW Steel City Senior Lending BDC reported total investments of $791.4 million as of September 30, 2026, with a portfolio primarily focused on debt investments across various industries including Building Products and Professional Services. The company maintains a significant position in short-term U.S. Treasury Bills and reported 19,659,875 common shares outstanding.

Key figure
Net income $7.39M · +427.8% YoY
6:05 AM ET 10-Q
Financial Results TCW Direct Lending VII LLC

TCW Direct Lending VII Q3 2026 Results: Net Loss of $22.5M

TCW Direct Lending VII LLC reported total investments of $1.16 billion at fair value as of September 30, 2026, with a significant concentration in debt investments across industries like Textiles, Apparel & Luxury Goods and Hotels, Restaurants & Leisure. The company's net assets stood at $400.2 million, supported by 13,734,010 common units outstanding.

Key figure
Net loss $22.5M
6:05 AM ET 10-Q
Financial Results TCW Direct Lending Viii LLC

TCW Direct Lending Viii Q3 2026 Results: Net Income $4.42M, Down 90.9% YoY

TCW Direct Lending VIII LLC reported a diverse portfolio of debt investments across industries such as automobile components, commercial services, and food products as of September 30, 2026. The company held 6,310,260 common units outstanding and maintained significant positions in term loans with varying SOFR-based interest rates and PIK components.

Key figure
Net income $4.42M · -90.9% YoY
6:05 AM ET 10-Q
Financial Results TCW Direct Lending LLC

TCW Direct Lending Q3 2026 Results: Net Loss of $5.99M, Loss Narrows

For the nine months ended September 30, 2026, TCW Direct Lending Strategic Ventures LLC reported a net decrease in members' capital from operations of $8.4 million, compared to a $4.2 million decrease in the prior year period. The decline was primarily driven by $9.7 million in net unrealized depreciation on affiliated investments, specifically related to SSI Parent, LLC common and preferred stock.

Key figure
Net loss $5.99M
6:05 AM ET 10-Q
Financial Results Reviva Pharmaceuticals Holdings, Inc. RVPH

Reviva Pharmaceuticals Holdings Q3 2026 Results: Net Loss of $2.3M, Loss Narrows

Reviva Pharmaceuticals reported a net loss of $7.9 million for the nine months ended September 30, 2026, a significant reduction from the $16.5 million loss in the prior year period. The company strengthened its liquidity through public and ATM offerings, ending the quarter with $17.5 million in cash and cash equivalents.

Key figure
Net loss $2.3M
6:05 AM ET 10-Q
Financial Results Bio Essence Corp BIOE

Bio Essence Q3 2026 Results: Net Loss of $150K

Bio Essence Corp. reported a net income of $324,992 for the nine months ended September 30, 2026, a significant improvement from a net loss of $132,890 in the prior year period. Despite this profitability, the company maintains a working capital deficit of $1,374,178 and an accumulated deficit of over $9.2 million, leading management to express substantial doubt about its ability to continue as a going concern.

Key figure
Net loss $150K
6:05 AM ET 8-K
Financial Results Reviva Pharmaceuticals Holdings, Inc. RVPH

Reviva Pharmaceuticals Holdings Financial Results

Reviva Pharmaceuticals reported a net loss of $2.3 million for the third quarter of 2026, an improvement from a $4.0 million loss in the prior year period. The company is awaiting FDA feedback in Q4 2026 regarding a new formulation of brilaroxazine for its Phase 3 RECOVER-2 trial in schizophrenia. Reviva also noted it has filed a new composition of matter patent application that could extend protection for brilaroxazine through 2046.

Term
Q3 2026

“Our near-term focus is obtaining Food and Drug Administration (FDA) feedback on the proposed use of a new formulation of brilaroxazine and preparing for the next stages of clinical development while managing our capital resources carefully.”

Laxminarayan Bhat, Founder, President, and CEO of Reviva

“We remain focused on disciplined execution as we advance brilaroxazine as a potentially differentiated treatment option for patients with schizophrenia.”

Laxminarayan Bhat, Founder, President, and CEO of Reviva
6:04 AM ET 10-Q
Financial Results Aardvark Therapeutics, Inc. AARD

Aardvark Therapeutics Q3 2026 Results: Net Loss of $19.2M, Loss Widens

Aardvark Therapeutics reported a net loss of $19.2 million for the third quarter of 2026, driven by increased research and development costs. The company's cash position remains at $60.3 million as it continues to transition from its 2025 initial public offering to fund its clinical-stage metabolic disease pipeline.

Key figure
Net loss $19.2M
6:04 AM ET 6-K
Financial Results Almonty Industries Inc. ALM

Almonty Industries Q3 2026 Results: Net Income $50.2M, Up 51.4% YoY

Almonty Industries reported a 382% year-over-year revenue increase to $41.9 million for Q3 2026, driven by a surge in tungsten prices and the commencement of commercial operations at the Sangdong Mine. Net income reached $50.2 million, supported by significant non-cash gains on derivative revaluations, while the company ended the quarter with a strong cash position of $1.15 billion.

Key figure
Net income $50.2M · +51.4% YoY
6:04 AM ET 10-Q
Financial Results Buda Juice, Inc. BUDA

Buda Juice Q3 2026 Results: Net Income $866K, Down 1.7% YoY

Buda Juice, Inc. reported net sales of $13.22 million for the nine months ended September 30, 2026, a significant increase from $9.71 million in the prior year. Following its January 2026 IPO and conversion to a C corporation, the company ended the period with $19.28 million in cash and cash equivalents, up from $1.84 million at the start of the year.

Key figure
Net income $866K · -1.7% YoY
6:04 AM ET 10-Q
Financial Results Realloys Inc. ALOY

Realloys Q3 2026 Results: Net Loss of $30.5M, Loss Widens

REALLOYS INC. reported a significant increase in net revenues to $1.92 million for the nine months ended September 30, 2026, compared to $0.63 million in the prior year, though it incurred a substantial net loss of $174.1 million driven by high general and administrative expenses and stock-based compensation. The company completed a reverse recapitalization in February 2026 and significantly strengthened its cash position to $116.2 million following various equity issuances.

Key figure
Net loss $30.5M
6:04 AM ET 8-K
Financial Results Skyx Platforms Corp. SKYX

Skyx Platforms Financial Results

SKYX Platforms reported record third-quarter revenue of $25.7 million, representing 7.4% year-over-year growth and its 11th consecutive quarter of growth. The company highlighted its recent merger with Deako, which expanded its builder channel pipeline to approximately 4 million units. Management noted a strong cash position of $21 million and believes it has sufficient capital to reach cash-flow positive status.

Term
Q3 2026
6:04 AM ET 8-K
Financial Results Nakamoto Inc. NAKA

Nakamoto Financial Results

Nakamoto Inc. reported Q3 2026 net income of $85.5 million, driven primarily by a $110.4 million gain in the fair value of its digital asset holdings. The company reported total operating revenue of $(1.9) million due to derivative losses and highlighted the extension of its Kraken loan facility maturity to December 2027.

Term
Q3 2026

“We spent the third quarter building. We launched Bitcoin Magazine TV to add year-round sponsorship revenue, took UTXO into structured credit, and held Bitcoin Asia in Hong Kong. We also announced Intelligence 2027, our first event built around AI. i27 takes our events business behind The Bitcoin Conference into the intersection between AI, investment, enterprise adoption and policy.”

David Bailey, Chairman and Chief Executive Officer of Nakamoto

“Markets move in cycles, and we are building Nakamoto to perform through all of them, by extending our debt maturities and building operating businesses that earn revenue beyond our Bitcoin holdings. We are confident that these initiatives and our selective approach to deploying capital will help us drive sustainable earnings and long-term shareholder value.”

David Bailey, Chairman and Chief Executive Officer of Nakamoto
6:04 AM ET 10-Q
Financial Results Enovix Corp ENVX

Enovix Q3 2026 Results: Net Loss of $41.9M, Loss Narrows

Enovix Corp reported revenue of $11.0 million for the fiscal quarter ended October 4, 2026, up from $8.0 million in the prior year period. The company reduced its quarterly loss from operations to $39.3 million compared to $47.0 million in 2025, while maintaining a strong liquidity position with $405.5 million in cash and short-term investments.

Key figure
Net loss $41.9M
6:04 AM ET 10-Q
Financial Results HawkEye 360, Inc. HAWK

HawkEye 360 Q3 2026 Results: Net Loss of $163K

HawkEye 360, Inc. significantly strengthened its balance sheet in 2026, with cash and cash equivalents increasing to $494.9 million from $92.7 million at year-end 2025. The company transitioned from a stockholders' deficit to a total stockholders' equity of $805.3 million, primarily driven by the conversion of mezzanine equity and an increase in additional paid-in capital.

Key figure
Net loss $163K
6:04 AM ET 10-Q
Financial Results Gemini Space Station, Inc. GEMI

Gemini Space Station Q3 2026 Results: Net Loss of $58.6M, Loss Narrows

Gemini Space Station, Inc. reported a total asset decrease from $1.80 billion at year-end 2025 to $1.58 billion as of September 30, 2026, driven by declines in cash and crypto assets held. The company's accumulated deficit widened to $2.32 billion, reflecting ongoing net losses during the period.

Key figure
Net loss $58.6M
6:04 AM ET 10-Q
Financial Results Cartesian Growth Corp IV CGCF

Cartesian Growth Corp IV Q3 2026 Results: Net Income $2.34M

Cartesian Growth Corporation IV is a blank check company that completed its IPO in June 2026, raising $275 million. As of September 30, 2026, the company reported a net income of $2.3 million for the quarter, primarily driven by interest earned on investments held in the Trust Account, and is currently seeking a target for a business combination.

Key figure
Net income $2.34M
6:03 AM ET 10-Q
Financial Results GigCapital9 Corp. GIX

GigCapital9 Q3 2026 Results: Net Income $1.98M

GigCapital9 Corp. is a shell company that completed its initial public offering in January 2026, raising $253 million. For the nine months ended September 30, 2026, the company reported net income of $5.1 million, primarily driven by $6.1 million in interest and dividend income from marketable securities held in its Trust Account.

Key figure
Net income $1.98M
6:03 AM ET 10-Q
Financial Results Nova Minerals Corp NVA

Nova Minerals Q1 2026 Results: Net Loss of $12M, Loss Widens

Nova Minerals Corp reported a net loss of $12.0 million for the quarter ended September 30, 2026, compared to a $6.4 million loss in the prior year, driven primarily by increased exploration and evaluation expenses. The company is transitioning its focus toward developing a pilot-scale antimony processing facility in Alaska, supported by a $43.4 million award from the U.S. Department of War.

Key figure
Net loss $12M
6:03 AM ET 10-Q
Financial Results Silence Therapeutics plc SLN

Silence Therapeutics Q3 2026 Results: Net Loss of $12.4M, Loss Narrows

Silence Therapeutics reported a net loss of $39.7 million for the nine months ended September 30, 2026, a significant improvement from the $76.8 million loss in the prior year period. The company strengthened its balance sheet through a major share issuance in the third quarter, bringing cash and cash equivalents to $247.7 million, which management believes will fund operations until at least 2028.

Key figure
Net loss $12.4M
6:03 AM ET 10-Q
Financial Results York Space Systems Inc. YSS ▶ Call

York Space Systems Q3 2026 Results: Net Loss of $807M, Loss Widens

York Space Systems Inc. reported a significant increase in total current assets to $579.2 million as of September 30, 2026, driven by growth in cash and contract assets. The company is actively executing an M&A strategy, highlighting recent acquisitions of Orbion Space Technologies, Solestial Space Technology, and All.Space Holdings.

Key figure
Net loss $807M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.